ACIP Presentation Slides: October 20-21, 2021 Meeting

Note: These files are not yet 508

Slides will be added as they become available.

October 20, 2021

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Pneumococcal Vaccines

• Introduction pdf icon[10 pages]
  Dr. K Poehling
  
• Considerations for age-based and risk-based use of PCV15/PCV20 among adults and proposed policy options pdf icon[56 pages]
  Dr. M Kobayashi

Zoster Vaccines

• Introduction pdf icon[10 pages]
  Dr. C Kotton
  
• Work group interpretation of the EtR regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options pdf icon[75 pages]
  Dr. T Anderson

Influenza Vaccines

• Introduction pdf icon[4 pages]
  Dr. K Talbot
  
• Phase II safety and immunogenicity study of the coadministration of Fluzone® High-Dose Quadrivalent Influenza Vaccine and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) pdf icon[23 pages]
  Dr. R Izikson
• Change in Age Indication for Flucelvax Quadrivalent pdf icon[7 pages]
  Dr. L Grohskopf

October 21, 2021

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Coronavirus Disease 2019 (COVID-19) Vaccines

• Introduction pdf icon[10 pages]
  Dr. M Daley
  
• Moderna- Booster dose data pdf icon[33 pages]
  Dr. J Miller
• Janssen- Booster dose data pdf icon[33 pages]
  Dr. P Heaton & Dr. M Douoguih
• National Instututues of Health, Mix and Match booster study pdf icon[17 pages]
  Dr. R Atmar
• v-safe and VAERS – third dose and simultaneous vaccination pdf icon[24 pages]
  Dr. A Hause
• COVID-19 Vaccine Safety Updates pdf icon[33 pages]
  Dr. T Shimabukuro
• Myocarditis- VAERS pdf icon[15 pages]
  Dr. J Su
• Myocarditis- VSD pdf icon[30 pages]
  Dr. N Klein
• VaST Assessment pdf icon[16 pages]
  Dr. K Talbot
• COVID-19 vaccine effectiveness, primary series pdf icon[90 pages]
  Dr. J Jones
• Evidence to Recommendations pdf icon[44 pages]
  Dr. K Dooling
• Clinical considerations pdf icon[17 pages]
  Dr. S Reddy
• Policy Questions
  Dr. K Dooling